Showing 1 - 4 results of 4 for search 'Georgi Shukarev', query time: 0.02s Refine Results
  1. 1
    A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

    A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks by Georgi Shukarev, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, the EBOVAC1 consortium

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

    Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults by Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

    Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda by Jonathan Kitonsa, Abu-Baker Ggayi, Zacchaeus Anywaine, Eva Kisaakye, Laura Nsangi, Vincent Basajja, Mary Nyantaro, Deborah Watson-Jones, Georgi Shukarev, Ine Ilsbroux, Cynthia Robinson, Pontiano Kaleebu

    Published 2020
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

    Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in in... by Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: